CYTOMX THERAPEUTICS INC
NASDAQ: CTMX (CytomX Therapeutics, Inc.)
最近更新时间: 27分钟之前2.02
-0.02 (-1.23%)
新闻情绪
AIStockmoo 评分
| 价值 30% | 3.4 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对其盈利增长,估值偏低。 参考 | |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力强。短期流动性充足。现金流为负。 参考 | |
| 资本回报 参考 | NA |
| 时机 30% | -4.0 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| K线形态 参考 | NA |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 聪明钱 20% | -0.7 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净-0.08%的股份:114家增持,75家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+35.0%,回补天数12天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 股价处于支撑位与阻力位之间。支撑与阻力水平趋升。 参考 | |
| 最终评分 | -0.30 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | CytomX Therapeutics, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| CTMX | - | - | - | 1.55 |
| OPT | 583 M | - | - | 4.31 |
| OCUP | 51 M | - | - | 0.870 |
| ZYME | - | - | - | 7.29 |
| PBYI | - | - | - | 2.73 |
| ORMP | - | 6.74% | - | 0.530 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.83% |
| 机构持股比例 | 47.10% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Elmind Capital, Lp | 30 Jun 2026 | 4,550,000 |
该时间范围内无数据。
机构
机构持股比例: 103.35%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 114 | 29,761,343 |
| 减持 | 75 | 28,757,015 |
| 新建仓 | 46 | 5,112,628 |
| 清仓 | 32 | 6,286,727 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 45,246,966 | 12.0 |
| 15 Oct 2026 | 42,790,446 | 13.8 |
| 30 Sep 2026 | 40,813,393 | 8.7 |
| 15 Sep 2026 | 38,639,220 | 9.3 |
| 31 Aug 2026 | 33,512,293 | 11.8 |
| 14 Aug 2026 | 34,619,999 | 15.9 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
CytomX (CTMX) Q3 2026 Earnings Call Transcript
Lower diarrhea rates emerge, but toxicity control remains the key test. |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics Q3 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027. The update is expected to include the first look at overall survival data… |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 0.00% and -59.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — CytomX Therapeutics Inc. |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase… |
| 02 Nov 2026 | Yahoo Finance |
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November. Guggenheim 3rd Annual… |
| 29 Oct 2026 | Yahoo Finance |
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S.… |
| 01 Sep 2026 | Yahoo Finance |
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Wells Fargo 21st Annual… |
| 27 Aug 2026 | Yahoo Finance |
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.… |
投资组合